Loading…
← CockpitCompetitor Analysis › KLRA Kailera Therapeutics, Inc.Open in the cockpit ↗

Kailera Therapeutics, Inc.KLRACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.

Momentum laggard 16
Mkt cap
$1.53B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$10.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-96.1 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$11.79
1D-3.4%
1W-18.0%
1M-8.5%
3M-32.5%
6M-41.3%
YTDn/a
1Yn/a
ATR %8.1%
52w lowhigh58.2% off high

What Kailera Therapeutics does

Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.

Has no medicine on sale, so it funds studies with money raised from investors. It holds the rights outside China to drugs developed by a Chinese partner, under licence terms that normally include milestone and royalty payments, and would earn from sales only after regulators approve a product.

Products and services

  • Licensed GLP-1/amylin/glucagon pipeline (ex-China rights)

Customers

  • Endocrinologists/obesity specialists (post-approva

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • GLP-1/obesity and metabolic…

What could go right

  • Large and fast-growing obesity drug market
  • Late-stage licensed assets shorten development time

What could go wrong

  • Intensely crowded GLP-1/obesity competitive field
  • Dependence on licensing partner data quality

Moat: narrow (IP / patents, regulatory licence). Backed by major biotech investors with licensed clinical-stage assets in the crowded obesity/GLP-1 race.

Headquarters: Boston, Massachusetts, US · Founded: 2024 · Employees: 145

Named competitors

Kailera Therapeutics at a glance

Size Kailera Therapeutics (KLRA) is a United States Health Care company (Biotechnology) with a market value of $1.53B, the 1961st largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.79 on 18 Nov 2026.

Performance Over six months the shares fell 41.3%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Capital Return on invested capital runs 96.1 points below its cost of capital (6.6% WACC).

Short interest Short interest is 6.3% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 92KLRA 56
Six months, rebased to 100: Kailera Therapeutics against the median of its 20 peers (local-currency closes).

Kailera Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$310,000-$53,000
EBITDAn/a-$158M-$16.3M
Net incomen/a-$149M-$220M
Free cash flown/a-$122M-$124M
Capital expendituren/a$2.09M$262,000
Total debt$9.97M$10.8M$509,000

Quarterly statements and history in the cockpit →

Kailera Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%PGENNRIXKRSA688319VIR087010MSB2637URGNPPGN6887656949688222ALVOANIP600226688105QUREKLRA6-month return →1-month return →
Up and to the right = strong over both horizons. Kailera Therapeutics is the large dot.

Kailera Therapeutics competitors and peer comparison

Head to head with its named competitors (KLRA vs NOVO-B.CO vs LLY vs VKTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Kailera Therapeutics KLRA$1.53B-41%n/an/an/an/a
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Viking Therapeutics VKTX$3.34B-9%n/an/an/an/a

How Kailera Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kailera Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureKLRAPeer medianRank in peer set
1-month return-8.5%-12.9%8th highest of 21
6-month return-41.3%-6.9%3rd lowest of 20
Distance from 52-week high-58.2%-44.5%5th lowest of 21
ROIC minus cost of capital-96.1 pp-6.4 pplowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a

Questions

Who are Kailera Therapeutics's main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY), Viking Therapeutics (VKTX). The cockpit's measured peer set (industry) also includes Precigen (PGEN), Nurix Therapeutics (NRIX), Korsana Biosciences (KRSA), Chengdu Olymvax Biopharmaceuticals (688319.SS), TLC BioSciences (7924.TWO), Vir Biotechnology (VIR).
How has Kailera Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -41.3% against -6.9% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.